HSV-2 can be hard to pin down at the person level, yet the lab picture is remarkably sharp, with Western blot accuracy reported at 99% sensitivity and 99% specificity and PCR catching over 95% of cases during outbreaks. Still, the bigger story is how that infection persists quietly, with asymptomatic shedding occurring on 15 to 30% of days and genital-to-genital contact driving 85 to 90% of transmissions. NHANES 2015 to 2016 finds 11.9% seroprevalence in US adults aged 14 to 49, while globally about 491 million people aged 15 to 49, or 13%, are living with HSV-2 in 2020.
Key Takeaways
- HSV-2 Western blot detects infection with 99% sensitivity and 99% specificity
- Type-specific IgG ELISA (HerpeSelect) has 96% sensitivity for HSV-2
- PCR of lesion swabs detects HSV-2 DNA with >95% sensitivity during outbreaks
- In the United States, the seroprevalence of HSV-2 among persons aged 14-49 years is 11.9% according to NHANES 2015-2016 data
- Globally, an estimated 491 million people aged 15-49 years (13%) were living with HSV-2 infection in 2020
- HSV-2 prevalence among women aged 14-49 in the US is 15.9%, higher than 8.2% in men, per CDC NHANES data
- Initial genital herpes outbreaks present with painful vesicles or ulcers in 70-90% of symptomatic cases
- Prodromal symptoms like tingling or burning precede outbreaks in 50% of patients
- Recurrent genital herpes episodes average 4-5 per year initially, decreasing to 1-2 over time
- HSV-2 is transmitted primarily through genital-to-genital contact, accounting for 85-90% of cases
- The risk of HSV-2 transmission from infected male to female per act of vaginal sex is 2.7% without condom
- Condom use reduces HSV-2 transmission risk by 30-50% in discordant couples
- Daily valacyclovir 500mg reduces recurrences by 70-80%
- Episodic acyclovir 400mg TID x5 days shortens outbreak duration by 1.5 days
- Famciclovir 125mg BID suppressive equivalent to acyclovir 400mg BID
HSV-2 is widespread worldwide and often silent, but testing and antivirals can substantially reduce transmission and outbreaks.
Related reading
01 · Category
Diagnosis And Testing29 stats
01
HSV-2 Western blot detects infection with 99% sensitivity and 99% specificity
02
Type-specific IgG ELISA (HerpeSelect) has 96% sensitivity for HSV-2
03
PCR of lesion swabs detects HSV-2 DNA with >95% sensitivity during outbreaks
04
Seroconversion to HSV-2 IgG takes 12-23 weeks post-infection in 95% cases
05
NAAT (nucleic acid amplification test) preferred for anogenital swabs, sensitivity 98%
06
False positive rate for commercial HSV-2 IgG tests is 10-50% at low indices
07
Viral culture sensitivity only 50-70% from lesions, lower if delayed
08
Focus ELISA index value >3.5 indicates true positivity >95%
09
IgM tests unreliable for HSV-2 diagnosis, not recommended by CDC
10
CSF PCR positive in 70-90% of HSV-2 aseptic meningitis cases
11
Point-of-care tests like HerpeSpot have 85% sensitivity for lesions
12
Type-specific serology detects 70-80% of infections at 6 months post-exposure
13
Multispot HSV-1/HSV-2 rapid test approved, 97% HSV-2 specificity
14
Tzanck smear shows multinucleated giant cells in 60% vesicular lesions
15
Biotin interference affects some HSV IgG assays, resolved by incubation
16
HSV-2 PCR on blood rare, not routine for disseminated disease
17
Western blot confirmatory test gold standard, PPV 99% at low prevalence
18
Self-collected vaginal swabs for HSV PCR 95% concordant with clinician swabs
19
IgG seroprevalence surveys use type-specific assays like Captia
20
Antigen detection tests (DFA) sensitivity 80-90% on lesion scrapings
21
Retesting recommended if index 1.1-3.5 on HerpeSelect
22
HSV-2 DNA PCR detects asymptomatic shedding reliably (subclinical)
23
Cross-reactivity minimal in type-specific gG2-based assays (<2%)
24
Prenatal HSV-2 screening not routine, but type-specific IgG if history
25
qPCR quantifies HSV-2 load, correlates with transmission risk
26
Liaison HSV-1/2 IgG assay 98% sensitivity/specificity for HSV-2
27
Oral fluid HSV-2 IgG detection inferior (60% sensitivity)
28
Roche cobas HSV-1/2 assay automated, 100% specificity HSV-2
29
Acyclovir resistance rare in immunocompetent (0.1-0.5%), tested by plaque reduction
Interpretation
Diagnosis And Testing Interpretation
For diagnosis and testing, the most actionable trend is that while tests like HSV-2 Western blot and lesion PCR can reach about 99% sensitivity and specificity and NAAT for anogenital swabs is 98% sensitive, commercial HSV-2 IgG tests can still have a 10% to 50% false positive rate at low indices, so results often need careful interpretation.
02 · Category
Prevalence And Incidence30 stats
01
In the United States, the seroprevalence of HSV-2 among persons aged 14-49 years is 11.9% according to NHANES 2015-2016 data
02
Globally, an estimated 491 million people aged 15-49 years (13%) were living with HSV-2 infection in 2020
03
HSV-2 prevalence among women aged 14-49 in the US is 15.9%, higher than 8.2% in men, per CDC NHANES data
04
In sub-Saharan Africa, HSV-2 seroprevalence among adults aged 15-49 reaches up to 50-80% in some populations
05
Lifetime risk of acquiring HSV-2 in the US is approximately 1 in 6 for people aged 14-49
06
HSV-2 incidence rate among HSV-1 seronegative women in the US is 2.3 per 1,000 person-years
07
In Europe, HSV-2 seroprevalence is around 5-10% in the general adult population, varying by country
08
Among pregnant women in the US, HSV-2 seroprevalence is 22%
09
HSV-2 prevalence increases with age, from 1.4% in 14-19 year olds to 25.6% in 40-49 year olds in the US
10
In Latin America, HSV-2 seroprevalence among antenatal clinic attendees averages 30-40%
11
HSV-2 seroprevalence among non-Hispanic black women in the US is 48.4%
12
Annual incidence of HSV-2 in the US general population is estimated at 0.5-1% among adults
13
In Asia, HSV-2 prevalence is lower at 5-15% among adults aged 15-49
14
HSV-2 seroprevalence among men who have sex with men (MSM) in the US is 20-30%
15
In Australia, HSV-2 seroprevalence is 12% in women and 6% in men aged 20-59
16
HSV-2 prevalence among female sex workers in sub-Saharan Africa exceeds 70%
17
In the UK, HSV-2 seroprevalence is 8-10% in adults under 50
18
HSV-2 incidence among discordant couples is 5-10% per year without condoms
19
In India, HSV-2 seroprevalence among pregnant women is 15-20%
20
US HSV-2 prevalence declined from 16.0% in 1999-2000 to 11.9% in 2015-2016
21
HSV-2 seroprevalence in Canadian adults is approximately 15%
22
Among US Hispanics, HSV-2 prevalence is 10.7% for ages 14-49
23
In South Africa, HSV-2 prevalence among young women aged 18-24 is 30-40%
24
HSV-2 seroprevalence among Asian Americans is 4.5%
25
Global HSV-2 incidence in 2020 was 25.6 million new cases among 15-49 year olds
26
In Brazil, HSV-2 seroprevalence among blood donors is 15%
27
HSV-2 prevalence among non-Hispanic whites in US is 8.1%
28
In Kenya, HSV-2 seroprevalence in fishermen communities is over 60%
29
HSV-2 incidence rate in serodiscordant heterosexual couples is 4.3 per 100 person-years
30
In Western Europe, HSV-2 seroprevalence has stabilized at 5-8% over the past decade
Interpretation
Prevalence And Incidence Interpretation
Across the prevalence and incidence data, HSV-2 remains highly common with 11.9% of US adults aged 14 to 49 seropositive and 15.9% prevalence in women, while globally about 491 million people aged 15 to 49 lived with HSV-2 in 2020 and the lifetime risk in the US is roughly 1 in 6.
03 · Category
Symptoms And Clinical Manifestations30 stats
01
Initial genital herpes outbreaks present with painful vesicles or ulcers in 70-90% of symptomatic cases
02
Prodromal symptoms like tingling or burning precede outbreaks in 50% of patients
03
Recurrent genital herpes episodes average 4-5 per year initially, decreasing to 1-2 over time
04
Aseptic meningitis occurs in 36% of primary HSV-2 infections
05
Urinary retention due to sacral radiculitis in 10-20% of primary outbreaks
06
Systemic symptoms (fever, malaise) in 40-60% of first-episode HSV-2 cases
07
Pain score during outbreaks averages 6-8 on VAS 0-10 scale
08
Lesions heal in 7-10 days for primary, 5-7 days for recurrent episodes
09
Neuralgia persists >1 month in 10-15% of recurrent cases
10
80-90% of HSV-2 infections are asymptomatic or unrecognized
11
Erythema multiforme associated with HSV-2 in 15% of recurrent cases
12
Outbreak duration shortened by 1-2 days with episodic antivirals
13
Sacral paresthesias in 20-30% during primary infection
14
Lymphadenopathy in 60-80% of symptomatic primary episodes
15
Herpetic whitlow (finger lesions) from autoinoculation in <5% cases
16
Mean outbreak frequency 1.5 episodes/year after 5 years infection
17
Dysuria in 30-50% of women during outbreaks
18
Extragenital lesions (buttocks, thighs) in 20-30% recurrences
19
Headache and photophobia in meningeal HSV-2 (25% cases)
20
Quality of life reduced by 20-30% during outbreaks per SF-36 scores
21
Primary infection lesion number averages 15-20 vesicles/ulcers
22
Recurrent episodes milder, with 2-5 lesions typically
23
Fatigue reported in 50% of primary symptomatic cases
24
HSV-2 proctitis in 20-30% of MSM with anal-receptive intercourse
25
Postherpetic neuralgia duration averages 2-4 weeks in 5-10%
26
Cervical lesions in 70-90% of primary HSV-2 in women, often asymptomatic
27
Myalgias in 20-30% during first episode
28
Prodrome lasts 1-2 days, with itching in 46%, tingling 65%
29
Depression/anxiety elevated 2-fold in diagnosed HSV-2 patients
30
Lesion crusting occurs by day 4-5 in recurrences
Interpretation
Symptoms And Clinical Manifestations Interpretation
In the Symptoms And Clinical Manifestations of HSV-2, first episodes commonly involve systemic illness and severe local lesions, with fever or malaise in 40 to 60% of cases and painful vesicles or ulcers in 70 to 90%, while recurrences typically start at 4 to 5 per year and gradually fall to 1 to 2 over time.
More related reading
04 · Category
Transmission And Risk Factors29 stats
01
HSV-2 is transmitted primarily through genital-to-genital contact, accounting for 85-90% of cases
02
The risk of HSV-2 transmission from infected male to female per act of vaginal sex is 2.7% without condom
03
Condom use reduces HSV-2 transmission risk by 30-50% in discordant couples
04
Asymptomatic viral shedding occurs on 15-30% of days in HSV-2 infected individuals
05
HIV-positive individuals have 2-3 times higher risk of HSV-2 acquisition
06
Number of lifetime sexual partners is the strongest predictor of HSV-2 seropositivity, with OR 1.8 per additional partner
07
Female-to-male HSV-2 transmission risk per vaginal sex act is 1.0%
08
Oral sex transmits HSV-2 rarely, less than 1% of cases
09
HSV-2 acquisition risk is 3-fold higher in women than men
10
Antiretroviral therapy reduces HSV-2 shedding by 50% in HIV/HSV-2 co-infected persons
11
History of other STIs increases HSV-2 risk by 2-4 fold
12
Daily suppressive acyclovir reduces HSV-2 transmission by 48% in discordant couples
13
Younger age at sexual debut (<16 years) associates with 1.5-2.0 OR for HSV-2 infection
14
Circumcision reduces HSV-2 acquisition in men by 28-34%
15
High viral load during shedding increases transmission probability 10-fold
16
Partner concurrency doubles HSV-2 acquisition risk
17
HSV-2 transmission risk highest during first 6 months post-infection (10x asymptomatic baseline)
18
Low socioeconomic status correlates with 1.5-2.0 higher HSV-2 prevalence
19
Black race/ethnicity independently increases HSV-2 risk (OR 3.5) after adjusting for behaviors
20
Alcohol use before sex raises HSV-2 acquisition risk by 1.4 OR
21
HSV-2 shedding frequency is 20.1% of days in first year post-infection
22
Serodiscordant couples using condoms 100% reduce transmission by 50%
23
Smoking increases HSV-2 risk by 1.3-1.6 OR in cohort studies
24
HSV-2 transmission via autoinoculation from HSV-1 oral herpes is rare (<1%)
25
High education level inversely correlates with HSV-2 seroprevalence (OR 0.7)
26
PrEP users have similar HSV-2 incidence to non-users (no protective effect)
27
HSV-2 shedding more frequent in immunocompromised (35-50% days)
28
Early age first intercourse with older partner increases risk 2-fold
29
Daily valacyclovir reduces transmission by 48% (95% CI 15-71%)
Interpretation
Transmission And Risk Factors Interpretation
Within the transmission and risk factors, HSV-2 spreads mainly through genital-to-genital contact, and per-act vaginal sex carries a 2.7% transmission risk from men to women without condoms while asymptomatic shedding happens on 15 to 30% of days, making partner count the strongest predictor with an odds ratio of 1.8 for each additional partner.
05 · Category
Treatment And Management29 stats
01
Daily valacyclovir 500mg reduces recurrences by 70-80%
02
Episodic acyclovir 400mg TID x5 days shortens outbreak duration by 1.5 days
03
Famciclovir 125mg BID suppressive equivalent to acyclovir 400mg BID
04
Neonatal HSV mortality reduced from 60% to 6% with high-dose acyclovir IV
05
Suppressive therapy halves transmission risk (48% reduction, 95% CI 15-71%)
06
Acyclovir 400mg TID x7-10 days for primary episode, heals 80% by day 7
07
Vaccine trials (Herpevac) showed 73% efficacy against HSV-2 disease in women
08
Foscarnet for acyclovir-resistant HSV-2, 70-90% response rate
09
Topical acyclovir 3% ointment reduces healing time by 0.5-1 day, less effective
10
Long-term suppressive therapy safe >5 years, no resistance emergence
11
Valacyclovir 1g daily reduces shedding by 48%, recurrences by 74%
12
Cesarean delivery reduces neonatal transmission from 34% to 1-3%
13
Penciclovir cream shortens recurrent lesion pain by 0.7 days
14
HIV co-infected benefit from higher dose acyclovir 400-800mg TID
15
Patient-initiated episodic therapy within 1 day of prodrome most effective
16
Docosanol 10% cream reduces healing time by 18 hours vs placebo
17
No cure exists; antivirals palliative, recurrence rate 25-50% first year off therapy
18
Imiquimod topical ineffective for HSV-2 lesions
19
Counseling reduces psychosocial distress by 30-40% in new diagnoses
20
Helium-neon laser therapy shortens healing by 3.5 days in small trials
21
Acyclovir prophylaxis in late pregnancy reduces lesions at delivery 75%
22
Generics cost $10-20/month for suppressive valacyclovir 500mg daily
23
mRNA-1608 vaccine phase 1/2 showed 80% reduction in shedding
24
Lidocaine-prilocaine cream reduces lesion pain 40-50%
25
Behavioral interventions reduce recurrences by 20% via stress management
26
Cidofovir for resistant cases, 90% clinical response IV
27
Suppressive famciclovir 250mg BID prevents 82% of recurrences
28
No benefit from lysine supplementation (1-3g/day) in meta-analyses
29
Prophylactic acyclovir in neonates post-exposure prevents 80% dissemination
Interpretation
Treatment And Management Interpretation
In treatment and management of HSV2, suppressive and high dose antiviral strategies consistently make a major difference, with daily valacyclovir 500 mg cutting recurrences by about 70 to 80% and high dose IV acyclovir reducing neonatal mortality from 60% to 6%.
report visual · Comparison
HSV-2 testing accuracy
Western blot and PCR show high sensitivity/specificity for detecting HSV-2, outperforming less sensitive options.
HSV-2 Western blot detects infection with 99% sensitivity and 99% specificity99%
PCR of lesion swabs detects HSV-2 DNA with >95% sensitivity during outbreaks
95%
Seroconversion to HSV-2 IgG takes 12-23 weeks post-infection in 95% cases
95%
Viral culture sensitivity only 50-70% from lesions, lower if delayed
-70%
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marie Larsen. (2026, February 13). Hsv2 Statistics. Gitnux. https://gitnux.org/hsv2-statistics
MLA
Marie Larsen. "Hsv2 Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hsv2-statistics.
Chicago
Marie Larsen. 2026. "Hsv2 Statistics." Gitnux. https://gitnux.org/hsv2-statistics.